- NCIt
- C40242
Loading cancer entity…
Loading cancer entity…
Clinical trials
18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02466971 |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials
| active not recruiting |
| Phase 3 |
| 450 |
| National Cancer Institute (NCI)NIH |
| 3 |
| Aug 21, 2026 |
| clinicaltrials |
| NCT02595879 | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |